Eupraxia Pharmaceuticals Inc. (EPRX)
TSX 
Summary
EPRX Chart
Wall Street Analysts Think Eupraxia Pharmaceuticals Inc. (EPRX) Could Surge 75.08%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 75.1% in Eupraxia Pharmaceuticals Inc. (EPRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Believe Eupraxia Pharmaceuticals Inc. (EPRX) Could Rally 85.12%: Here's is How to Trade
The consensus price target hints at an 85.1% upside potential for Eupraxia Pharmaceuticals Inc. (EPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Eupraxia Pharmaceuticals Inc. (EPRX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Eupraxia Pharmaceuticals Inc. ever had a stock split?
Eupraxia Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | James A. Helliwell CEO | TSX Exchange | CA29842P1053 ISIN |
| CA Country | 33 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Eupraxia Pharmaceuticals Inc. is a clinical stage biotech enterprise dedicated to the innovation, development, and commercialization of new technologies within the biotechnology field. Originally known as Plaza Capital Partners Inc., the company underwent a name change to Eupraxia Pharmaceuticals Inc. in May 2012, and was established in 2011. Positioned at the forefront of addressing unmet medical needs, Eupraxia operates from its headquarters in Victoria, Canada. It focuses on creating therapeutic solutions spanning various medical areas, including but not limited to pain management for knee osteoarthritis and treatments for eosinophilic esophagitis, alongside an investigative interest in oncology.
Products and Services
- EP-104IAR
- EP-104GI
- EP-104
- Oncology Research
Currently in Phase III clinical trials, EP-104IAR is developed by Eupraxia Pharmaceuticals as a leading candidate aiming to offer pain relief for individuals suffering from knee osteoarthritis. This product stands out as a promising solution for a condition that affects millions globally, by potentially providing patients with an effective treatment option that addresses an urgent unmet medical need.
In the midst of Phase II clinical trials, EP-104GI represents Eupraxia Pharmaceuticals' commitment towards treating eosinophilic esophagitis. This condition, an allergic inflammatory disease of the esophagus, can be debilitating for those affected, and EP-104GI is being developed to provide a much-needed treatment option.
Eupraxia is also pushing the boundaries with EP-104, a compound undergoing preclinical studies. This investigative product has a wider scope, being assessed for the treatment of various inflammatory joint conditions beyond knee osteoarthritis, including benign structures of the esophagus and potential epidural delivery methods. The versatility and scope of EP-104 underline Eupraxia's innovative approach towards developing healthcare solutions.
In addition to its primary product offerings, Eupraxia Pharmaceuticals is actively involved in the development of oncology treatments. The company is leveraging its biotechnological expertise to explore new cancer therapies, demonstrating its dedication to expanding its impact within the medical community.
